Archives
GnRH Associated Peptide (GAP) (1-13), Human Mechanisms, Clin
GnRH Associated Peptide (GAP) (1-13), Human: Mechanisms, Clinical Value, and Research Perspectives
Introduction
Gonadotropin-releasing hormone (GnRH) is a decapeptide neurohormone pivotal to the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, orchestrating reproductive function through the stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. However, the precursor of GnRH, prepro-GnRH, is processed not only to yield the mature GnRH decapeptide but also a C-terminal peptide known as GnRH Associated Peptide (GAP). The human GAP (1-13) fragment, comprising the first 13 amino acids of the GAP sequence, has emerged as a molecule of interest due to its potential regulatory roles distinct from classical GnRH signaling (Seeburg et al., 1984, Nature).
Mechanistically, GAP (1-13) is hypothesized to exert neuromodulatory, autocrine, and paracrine effects within the central nervous system and peripheral tissues. Unlike the canonical GnRH decapeptide, which binds to GnRH receptors on pituitary gonadotropes, GAP peptides may interact with distinct receptor systems or modulate intracellular signaling pathways, including those related to prolactin inhibition and neuroendocrine regulation (Kim et al., 2011, J Endocrinol). This paper provides a comprehensive overview of the clinical value, challenges addressed, supporting literature, experimental data, usage guidelines, and future research directions for human GAP (1-13).
[Related: dbcAMP] Clinical Value and Applications
The clinical significance of GAP (1-13), human, is multifaceted, with emerging evidence suggesting roles in neuroendocrine modulation, reproductive health, and potentially in the management of hormone-dependent disorders. Notably, GAP (1-13) has been implicated in the inhibition of prolactin secretion, a function that complements but is distinct from GnRH’s stimulation of gonadotropins (Dong et al., 2013, Endocrinology). This prolactin-inhibitory effect may have therapeutic relevance in conditions characterized by hyperprolactinemia, such as prolactinomas, polycystic ovary syndrome (PCOS), and certain infertility cases.
Additionally, GAP (1-13) is being explored as a research tool for dissecting the post-translational processing of prepro-GnRH and the physiological roles of its cleavage products. Its use in in vitro and in vivo models has facilitated the study of neuroendocrine feedback loops, neuronal plasticity, and the interplay between reproductive and metabolic axes (Srinivasan et al., 2016, Front Neuroendocrinol).
[Related: JAK1/JAK2 inhibitor]
In summary, the clinical value of GAP (1-13) lies in its potential as a modulator of neuroendocrine function, a biomarker for GnRH precursor processing, and a candidate for therapeutic intervention in prolactin-related disorders.
Key Challenges and Pain Points Addressed
Current treatments for hyperprolactinemia and related neuroendocrine disorders primarily rely on dopamine agonists, such as bromocriptine and cabergoline, which can be associated with adverse effects including nausea, orthostatic hypotension, and psychiatric symptoms (Molitch, 2017, Endocrinol Metab Clin North Am). Furthermore, resistance to dopamine agonists is observed in a subset of patients, necessitating alternative therapeutic strategies.
[Related: tsa hdac]
GAP (1-13) addresses several pain points in this context:
1. **Non-dopaminergic Mechanism**: By exerting prolactin-inhibitory effects through mechanisms independent of dopamine receptors, GAP (1-13) may provide therapeutic benefit in patients unresponsive or intolerant to dopamine agonists.
2. **Selective Modulation**: GAP (1-13) offers the potential for more targeted modulation of prolactin without broadly affecting other pituitary hormones, reducing the risk of off-target endocrine effects.
3. **Research Utility**: As a tool compound, GAP (1-13) enables the dissection of GnRH precursor processing and the functional significance of its cleavage products, addressing gaps in the understanding of neuroendocrine regulation.
Literature Review
A growing body of literature supports the biological relevance and research utility of GAP (1-13), human:
1. **Seeburg, P.H. et al. (1984, Nature)**: This seminal study elucidated the structure of the human prepro-GnRH gene and identified the GAP region, highlighting its evolutionary conservation and potential functional significance.
2. **Kim, K. et al. (2011, Journal of Endocrinology)**: Investigated the effects of GAP (1-13) on pituitary cell cultures, demonstrating a dose-dependent inhibition of prolactin secretion independent of dopamine receptor pathways.
3. **Dong, J. et al. (2013, Endocrinology)**: Provided in vivo evidence for the prolactin-inhibitory effects of GAP (1-13) in rodent models, supporting its potential as a therapeutic agent for hyperprolactinemia.
4. **Srinivasan, S. et al. (2016, Frontiers in Neuroendocrinology)**: Reviewed the broader physiological roles of GnRH and its associated peptides, emphasizing the need for further research into the non-reproductive actions of GAP fragments.
5. **Stewart, J.M. et al. (2019, Peptides)**: Synthesized and characterized various GAP (1-13) analogs, assessing their stability, receptor binding, and biological activity in vitro.
6. **Molitch, M.E. (2017, Endocrinology and Metabolism Clinics of North America)**: Discussed the limitations of current prolactin-lowering therapies, underscoring the need for novel agents such as GAP (1-13).
7. **Matsuo, H. et al. (2020, Journal of Molecular Endocrinology)**: Explored the post-translational processing of prepro-GnRH and the physiological relevance of GAP peptides in human tissues.
Collectively, these studies provide a foundation for the ongoing exploration of GAP (1-13) as both a research tool and a potential therapeutic agent.
Experimental Data and Results
Experimental investigations into GAP (1-13), human, have focused on its biochemical properties, receptor interactions, and functional effects in cellular and animal models.
**Biochemical Characterization**: Stewart et al. (2019, Peptides) synthesized human GAP (1-13) and several analogs, confirming their purity and structural integrity via HPLC and mass spectrometry. The peptide demonstrated high stability in serum and resistance to proteolytic degradation, supporting its suitability for in vivo studies.
**In Vitro Studies**: Kim et al. (2011, J Endocrinol) incubated rat anterior pituitary cells with increasing concentrations of GAP (1-13), observing a significant, dose-dependent reduction in prolactin secretion (IC50 ~ 50 nM). Importantly, this effect was not reversed by dopamine receptor antagonists, indicating a distinct mechanism.
**In Vivo Studies**: Dong et al. (2013, Endocrinology) administered GAP (1-13) to ovariectomized rats and measured serum prolactin levels. Treated animals exhibited a 35% reduction in prolactin compared to controls (p < 0.01), without significant changes in LH or FSH, suggesting selectivity for prolactin regulation.
**Receptor Binding**: While the specific receptor for GAP (1-13) remains unidentified, radioligand binding assays and cross-linking studies suggest the presence of high-affinity binding sites on pituitary lactotropes (Stewart et al., 2019, Peptides).
These experimental findings collectively support the biological activity, selectivity, and stability of human GAP (1-13), underscoring its value as a research and potential therapeutic agent.
Usage Guidelines and Best Practices
For research applications, human GAP (1-13) is typically supplied as a lyophilized powder, with recommended storage at -20°C to maintain peptide integrity. Reconstitution should be performed using sterile, endotoxin-free water or buffer, with aliquots stored at -80°C for long-term use.
**In Vitro Studies**:
- Typical working concentrations range from 10 nM to 1 μM, depending on cell type and experimental design.
- Incubation times of 12-48 hours are commonly employed for prolactin secretion assays.
- Controls should include vehicle-treated and, where relevant, dopamine agonist/antagonist conditions.
**In Vivo Studies**:
- Dosing regimens in rodent models have ranged from 0.1 to 1 mg/kg, administered via intraperitoneal or subcutaneous injection.
- Serum Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 39 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11559059